On this page
DealShare CEO Kamaldeep Singh quits for Indofast Energy as Truemeds acquisition talks near $90 Mn
Our read
DealShare will more likely than not be sold to Truemeds at a valuation about 95% below its peak, with the CEO's exit coming first.
For operators
DealShare's CEO is leaving for Indofast Energy while a Truemeds sale is in advanced talks, and with FY25 revenue down 13.3% to ₹432.4 Cr, value-commerce rivals should expect a leadership and strategy reset at a competitor that is shrinking.
Watch
Signed deal value below the just over $90 Mn in talks, at announcement, would mean the buyer holds leverage and investors take a cut deeper than 95%.
Ask next
What leadership moves matter this week?The report,
DealShare CEO Kamaldeep Singh stepped down to join Indofast Energy as CEO, as the startup holds advanced talks to be acquired by Truemeds at just over $90 Mn, a 95% drop from its peak valuation. FY25 revenue fell to ₹432.4 Cr.
| Metric | FY24 | FY25 |
|---|---|---|
| Revenue from operations | ₹499 Cr | ₹432.4 Cr |
| Net loss | ₹167.7 Cr | ₹87.7 Cr |
One email each morning: the day’s top moves in Indian retail, why each matters and what to watch. Free. Stop any time.
Who and when
From the report. Source details below
| DealShare FY24 revenue from operations: | ₹499 Cr |
|---|---|
| DealShare FY25 net loss: | ₹87.7 Cr |
| DealShare FY24 net loss: | ₹167.7 Cr |
| Revenue decline in FY25: | 13.3% |
| Total funds raised by DealShare: | nearly $400 Mn |
Why the change matters
Truemeds is nearing a deal for DealShare at just over $90 Mn, which sets a distressed-level price marker for sub-scale value-commerce assets and shows that buyers can get in cheaply while the target's revenue is falling.
What to watch next
- Successor or interim CEO named at DealShare
- FY26 revenue against FY25's ₹432.4 Cr
- Net loss against FY25's ₹87.7 Cr
- Regulatory or shareholder approvals filed for the Truemeds deal
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- DealShare's board is likely to name an interim or internal successor to Kamaldeep Singh while the Truemeds talks run.
- Truemeds is likely to sign a definitive agreement only after diligence on DealShare's falling revenue and narrowing losses.
- Existing DealShare investors are likely to accept a steep markdown from the peak unicorn valuation rather than fund another standalone round.
- Indofast Energy is expected to confirm Kamaldeep Singh's start date and role as CEO.
- Rival value-commerce and grocery platforms may court DealShare's suppliers and small-retailer customers during the transition.